RVPG
ABBV icon

Relative Value Partners Group’s AbbVie ABBV Stock Holding History

Relative Value Partners Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		$5.06M Buy
29,525
+19,227
+187% +$3.18M 0.66% 32
2024
Q1 		$1.69M Sell
10,298
-164
-2% -$28.3K 0.1% 117
2023
Q4 		$1.62M Sell
10,462
-128
-1% -$18.7K 0.1% 124
2023
Q3 		$1.58M Buy
10,590
+2,110
+25% +$310K 0.11% 116
2023
Q2 		$1.14M Sell
8,480
-1,784
-17% -$262K 0.07% 135
2023
Q1 		$1.63M Sell
10,264
-637
-6% -$97.4K 0.11% 112
2022
Q4 		$1.76M Buy
10,901
+3,648
+50% +$559K 0.12% 114
2022
Q3 		$973K Buy
+7,253
New +$1.04M 0.08% 129
2022
Q2 		– Sell
-9,473
Closed -$1.54M – 174
2022
Q1 		$1.54M Buy
9,473
+3,675
+63% +$534K 0.11% 110
2021
Q4 		$785K Hold
5,798
– – 0.06% 115
2021
Q3 		$625K Sell
5,798
-539
-9% -$61.6K 0.05% 120
2021
Q2 		$714K Sell
6,337
-1,571
-20% -$177K 0.06% 111
2021
Q1 		$856K Buy
7,908
+118
+2% +$12.6K 0.07% 109
2020
Q4 		$835K Buy
7,790
+1,725
+28% +$166K 0.08% 100
2020
Q3 		$531K Hold
6,065
– – 0.06% 114
2020
Q2 		$595K Buy
6,065
+333
+6% +$29.3K 0.06% 102
2020
Q1 		$436K Buy
5,732
+3,333
+139% +$284K 0.05% 122
2019
Q4 		$212K Buy
+2,399
New +$199K 0.02% 159
2019
Q3 		– Sell
-4,043
Closed -$294K – 164
2019
Q2 		$294K Buy
4,043
+1,050
+35% +$82.5K 0.03% 130
2019
Q1 		$241K Buy
+2,993
New +$245K 0.03% 150
2018
Q4 		– Sell
-2,011
Closed -$190K – 156
2018
Q3 		$190K Buy
+2,011
New +$191K 0.02% 139
2015
Q4 		– Sell
-3,736
Closed -$203K – 136
2015
Q3 		$203K Buy
+3,736
New +$243K 0.02% 120

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Relative Value Partners Group's ABBV Position: Q2 2024 in Review

Relative Value Partners Group increased its AbbVie (ABBV) stake by 187% in Q2 2024, buying an estimated $3.18M and bringing the position to 29,525 shares worth $5.06M. The position accounts for 0.66% of the portfolio, ranked #32.

Relative Value Partners Group first reported a position in ABBV in Q3 2015 and has held it in 22 quarters since. 3,365 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

  • Relative Value Partners Group held 29,525 shares of AbbVie worth $5.06M as of Q2 2024.
  • Relative Value Partners Group bought 19,227 AbbVie shares in Q2 2024, an estimated $3.18M.
  • AbbVie made up 0.66% of Relative Value Partners Group's portfolio in Q2 2024, its #32 holding.
  • Relative Value Partners Group first reported a position in AbbVie in Q3 2015 and has held it in 22 quarters since.
  • 3,365 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Relative Value Partners Group's 13F filing for Q2 2024, filed 12 Jul 2024.